iShares MSCI Japan ETF vs Vaxcyte Inc. Common Stock — how do they compare? iShares MSCI Japan ETF trades at $94.54 (market cap $23.22B), while Vaxcyte Inc. Common Stock trades at $67.16 (market cap $10.63B). The key difference: iShares MSCI Japan ETF is far larger — about 2.2× Vaxcyte Inc. Common Stock's market cap, and iShares MSCI Japan ETF is more actively traded (5,587,717 versus 1,525,205). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 57 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| EWJ | PCVX | |
|---|---|---|
Market Cap | $23.22B | $10.63B |
Volume | 5,587,717 | 1,525,205 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $73.82 |
52-Week Low | $79.49 | $40.32 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $9.26B |
Signals from Pluang's Aura AI — not financial advice
EWJ, a US-listed ETF tracking Japanese equities, trades at $97.32 with no change on the day. Technical indicators show a bullish overall signal, with moving averages supporting an uptrend while oscillators remain neutral. Recent news highlights Japan's monetary policy shifts and international ETF outperformance, with the Nikkei 225 experiencing volatility amid rising bond yields and fiscal stimulus debates.
The outlook for EWJ is cautiously optimistic, driven by Japan's economic stimulus and potential yen strength, but risks include BOJ policy uncertainty and global yield pressures. Investors may find opportunity in Japan's AI and semiconductor exposure, though currency fluctuations and fiscal challenges pose headwinds for sustained gains.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →